CA2419033A1 - Traitement du syndrome de la resistance a l'insuline - Google Patents
Traitement du syndrome de la resistance a l'insuline Download PDFInfo
- Publication number
- CA2419033A1 CA2419033A1 CA002419033A CA2419033A CA2419033A1 CA 2419033 A1 CA2419033 A1 CA 2419033A1 CA 002419033 A CA002419033 A CA 002419033A CA 2419033 A CA2419033 A CA 2419033A CA 2419033 A1 CA2419033 A1 CA 2419033A1
- Authority
- CA
- Canada
- Prior art keywords
- ethyl
- dihydro
- pyrazolo
- pyrimidin
- sildenafil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne l'utilisation d'un inhibiteur sélectif de cGMP PDE5 ou d'une composition pharmaceutique de celui-ci dans la préparation d'un médicament pour le traitement curatif, palliatif ou prophylactique du syndrome de la résistance à l'insuline, ledit syndrôme étant caractérisé par l'existence concomitante chez un sujet de deux ou plusieurs des éléments suivants: la dyslipidémie; l'hypertension; le diabète sucré de type 2, l'affaiblissement de la tolérance au glucose (IGT) ou des antécédents familiaux de diabète; l'hyperuricémie et/ou la goutte; un état pro-coagulant; l'athérosclérose; ou l'obésité tronculaire. L'inhibiteur ci-dessus peut être utilisé seul ou en combinaison avec d'autres agents pour le traitement du syndrome de la résistance à l'insuline ou des aspects individuels du syndrome de résistance à l'insuline.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22492800P | 2000-08-11 | 2000-08-11 | |
US60/224,928 | 2000-08-11 | ||
GB0030649A GB0030649D0 (en) | 2000-12-15 | 2000-12-15 | Treatment of the insulin resistance syndrome |
GB0030649.8 | 2000-12-15 | ||
US26608301P | 2001-02-02 | 2001-02-02 | |
US60/266,083 | 2001-02-02 | ||
GB0106465.8 | 2001-03-15 | ||
GB0106468.2 | 2001-03-15 | ||
GB0106468A GB0106468D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of diabetes mellitus |
GB0106465A GB0106465D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of the insulin resistance syndrome |
GB0117134A GB0117134D0 (en) | 2001-07-13 | 2001-07-13 | Treatment of the insulin resistance syndrome |
GB0117134.7 | 2001-07-13 | ||
PCT/IB2001/001428 WO2002013798A2 (fr) | 2000-08-11 | 2001-08-06 | Traitement du syndrome de la resistance a l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2419033A1 true CA2419033A1 (fr) | 2002-02-21 |
Family
ID=27546614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002419033A Abandoned CA2419033A1 (fr) | 2000-08-11 | 2001-08-06 | Traitement du syndrome de la resistance a l'insuline |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1307183A2 (fr) |
JP (1) | JP2004506009A (fr) |
KR (1) | KR20030023747A (fr) |
CN (1) | CN1446084A (fr) |
AU (1) | AU2001276607A1 (fr) |
CA (1) | CA2419033A1 (fr) |
HU (1) | HUP0300725A3 (fr) |
IL (1) | IL154158A0 (fr) |
WO (1) | WO2002013798A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03006936A (es) * | 2001-02-02 | 2003-11-18 | Pfizer | Tratamiento de diabetes mellitus. |
JP4142356B2 (ja) | 2001-07-05 | 2008-09-03 | オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | Pp2cの基質 |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
CN1575191A (zh) | 2001-11-02 | 2005-02-02 | 辉瑞产品公司 | 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病 |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
AU2003205926A1 (en) * | 2002-02-07 | 2003-09-02 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
JP2004018524A (ja) * | 2002-06-13 | 2004-01-22 | Eucro European Contract Research Gmbh & Co Kg | 動脈硬化症を処置するための方法 |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
BRPI0408500A (pt) * | 2003-03-17 | 2006-03-07 | Pfizer Prod Inc | tratamento do diabetes do tipo 1 com inibidores de pde5 |
CN100439371C (zh) * | 2003-04-29 | 2008-12-03 | 辉瑞大药厂 | 可用于治疗高血压的5,7-二氨基吡唑并[4,3-d]嘧啶 |
OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
US7776893B2 (en) | 2003-09-05 | 2010-08-17 | Nycomed Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
DE602005011784D1 (de) | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
WO2006094933A1 (fr) | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast pour le traitement du diabete sucre |
WO2007010337A2 (fr) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes |
KR20090047546A (ko) | 2006-09-07 | 2009-05-12 | 니코메드 게엠베하 | 당뇨병을 위한 조합 치료 |
US8604245B2 (en) | 2007-06-04 | 2013-12-10 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
ES2625548T3 (es) | 2012-06-04 | 2017-07-19 | DiaMedica Therapeutics Inc. | Isoformas de glicosilación de la calicreína-1 tisular humana |
WO2014078459A1 (fr) * | 2012-11-13 | 2014-05-22 | Nusirt Sciences, Inc. | Compositions et méthodes permettant d'accroître le métabolisme énergétique |
AU2014202625B2 (en) | 2013-05-14 | 2018-11-08 | Scimar Ltd. | Hepatic insulin sensitizing substance and test meal for insulin sensitization |
CA2928725A1 (fr) | 2013-11-05 | 2015-05-14 | Esther Priel | Composes pour le traitement du diabete et des complications pathologiques qui en resultent |
JP2020510023A (ja) | 2017-03-09 | 2020-04-02 | ダイアメディカ, インコーポレイテッド | 組織カリクレイン1の剤形 |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
KR102068299B1 (ko) | 2018-12-21 | 2020-01-20 | 한국기초과학지원연구원 | Cyp4a 저해 화합물을 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
EA002357B1 (ru) * | 1995-12-28 | 2002-04-25 | Фудзисава Фармасьютикал Ко., Лтд. | Производные бензимидазола |
NZ338075A (en) * | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
CN1268942A (zh) * | 1997-06-27 | 2000-10-04 | 藤泽药品工业株式会社 | 磺酰胺化合物及其药物用途 |
EP1070705A4 (fr) * | 1998-04-06 | 2002-04-17 | Fujisawa Pharmaceutical Co | Derives d'indole |
CN1335847A (zh) * | 1998-12-04 | 2002-02-13 | 藤泽药品工业株式会社 | 磺酰胺化合物及其药物用途 |
WO2000056719A1 (fr) * | 1999-03-22 | 2000-09-28 | Bristol-Myers Squibb Company | Composes fusionnes de pyridopyridazine inhibiteurs de la cgmp phosphodiesterase |
DE19944161A1 (de) * | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
EP1088824B1 (fr) * | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Amides de pyrrole bicycliques comme inhibiteurs du glycogène phosphorylase |
CA2323008C (fr) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Composes pharmaceutiques actifs |
JP2004525857A (ja) * | 2000-04-19 | 2004-08-26 | ジョンズ・ホプキンス・ユニバーシティ | 胃腸疾患の予防および治療のための方法 |
-
2001
- 2001-08-06 IL IL15415801A patent/IL154158A0/xx unknown
- 2001-08-06 KR KR10-2003-7001961A patent/KR20030023747A/ko not_active Application Discontinuation
- 2001-08-06 HU HU0300725A patent/HUP0300725A3/hu unknown
- 2001-08-06 EP EP01954266A patent/EP1307183A2/fr not_active Withdrawn
- 2001-08-06 AU AU2001276607A patent/AU2001276607A1/en not_active Abandoned
- 2001-08-06 CN CN01814039A patent/CN1446084A/zh active Pending
- 2001-08-06 CA CA002419033A patent/CA2419033A1/fr not_active Abandoned
- 2001-08-06 WO PCT/IB2001/001428 patent/WO2002013798A2/fr not_active Application Discontinuation
- 2001-08-06 JP JP2002518944A patent/JP2004506009A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2004506009A (ja) | 2004-02-26 |
WO2002013798A3 (fr) | 2003-01-23 |
EP1307183A2 (fr) | 2003-05-07 |
HUP0300725A3 (en) | 2005-11-28 |
AU2001276607A1 (en) | 2002-02-25 |
HUP0300725A2 (hu) | 2003-11-28 |
WO2002013798A2 (fr) | 2002-02-21 |
IL154158A0 (en) | 2003-07-31 |
CN1446084A (zh) | 2003-10-01 |
KR20030023747A (ko) | 2003-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030166662A1 (en) | Treatment of the insulin resistance syndrome | |
CA2419033A1 (fr) | Traitement du syndrome de la resistance a l'insuline | |
US6683080B2 (en) | Treatment of diabetes mellitus | |
US6967204B2 (en) | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | |
JP2004527476A5 (fr) | ||
US20080153841A1 (en) | Treatment of premature ejaculation | |
US20050065158A1 (en) | Treatment of sexual dysfunction | |
US20040186046A1 (en) | Treatment of type 1 diabetes with PDE5 inhibitors | |
US20040029891A1 (en) | Use of PDE5 inhibitors in the treatment of polycystic ovary syndrome | |
EP1653966A1 (fr) | Traitement des dysfonctionnements sexuels | |
CA2519357A1 (fr) | Traitement du diabete insulino-dependant a l'aide d'inhibiteurs de pde5 | |
EP1335730B1 (fr) | Utilisation des inhibiteurs de pde5 pour le traitement de l'ejaculation precoce | |
AU2002215149A1 (en) | Treatment of premature ejaculation | |
AU2002328122A1 (en) | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |